Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Brooimans RA, van der Velden VHJ, Boeckx N, Slomp J, Preijers F, Te Marvelde JG, Van NM, Heijs A, Huys E, van der Holt B, de Greef GE, Kelder A, Schuurhuis GJ.

Leuk Res. 2019 Jan;76:39-47. doi: 10.1016/j.leukres.2018.11.014. Epub 2018 Nov 27.

2.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2018 Dec 12. doi: 10.1038/s41375-018-0326-3. [Epub ahead of print]

PMID:
30542144
3.

IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.

Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui ML, de Vos Klootwijk LLE, Menezes RX, Çil M, Roemer MGM, Vermue E, Heukelom S, Zweegman S, Janssen JJWM, Ossenkoppele GJ, Schuurhuis GJ, Smit L.

Cell Rep. 2018 Dec 11;25(11):3021-3035.e5. doi: 10.1016/j.celrep.2018.11.062.

4.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group, Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group.

Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15698. [Epub ahead of print] No abstract available.

PMID:
30520018
5.

Measurable residual disease in acute myeloid leukemia using flowcytometry: approaches for harmonization/standardization.

Schuurhuis GJ, Ossenkoppele GJ, Kelder A, Cloos J.

Expert Rev Hematol. 2018 Nov 23. doi: 10.1080/17474086.2018.1549479. [Epub ahead of print]

PMID:
30466339
6.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
7.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

8.

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J.

Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.

PMID:
29588393
9.

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.

Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J, Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G.

J Vis Exp. 2018 Mar 5;(133). doi: 10.3791/56386.

10.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

11.

Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.

Hanekamp D, Denys B, Kaspers GJL, Te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J, van der Velden VHJ.

Br J Haematol. 2018 Nov;183(3):512-516. doi: 10.1111/bjh.14991. Epub 2017 Oct 26. No abstract available.

PMID:
29076143
12.

The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.

van Solinge TS, Zeijlemaker W, Ossenkoppele GJ, Cloos J, Schuurhuis GJ.

Cytometry B Clin Cytom. 2018 Jan;94(1):151-158. doi: 10.1002/cyto.b.21539. Epub 2017 Aug 15.

13.

Leukemic stem cells: identification and clinical application.

Hanekamp D, Cloos J, Schuurhuis GJ.

Int J Hematol. 2017 May;105(5):549-557. doi: 10.1007/s12185-017-2221-5. Epub 2017 Mar 29. Review.

PMID:
28357569
14.

Cancer: A gene-expression profile for leukaemia.

Schuurhuis GJ.

Nature. 2016 Dec 15;540(7633):346-348. doi: 10.1038/nature20488. Epub 2016 Dec 7. No abstract available.

PMID:
27926735
15.

MRD in AML: does it already guide therapy decision-making?

Ossenkoppele G, Schuurhuis GJ.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365. Review.

16.

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J.

Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19.

17.

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S.

Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22.

18.

CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, Valk P, Ossenkoppele G, Zeijlemaker W, Kaspers G, Cloos J, Schuurhuis GJ.

Br J Haematol. 2016 Apr;173(2):219-35. doi: 10.1111/bjh.13941. Epub 2016 Jan 27.

PMID:
26814163
19.

Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis.

Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, Piersma SR, Knol JC, Pham TV, Jansen G, Musters RJ, van Meerloo J, Assaraf YG, Kaspers GJ, Zweegman S, Cloos J, Jimenez CR.

Mol Cell Proteomics. 2016 Apr;15(4):1281-98. doi: 10.1074/mcp.M115.052944. Epub 2016 Jan 22.

20.

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2016 Feb;30(2):439-46. doi: 10.1038/leu.2015.252. Epub 2015 Sep 16.

PMID:
26437777
21.

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2016 Mar;30(3):708-15. doi: 10.1038/leu.2015.255. Epub 2015 Sep 16.

PMID:
26373238
22.

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.

de Leeuw DC, Verhagen HJ, Denkers F, Kavelaars FG, Valk PJ, Schuurhuis GJ, Ossenkoppele GJ, Smit L.

Leukemia. 2016 Mar;30(3):742-6. doi: 10.1038/leu.2015.160. Epub 2015 Jun 25. No abstract available.

PMID:
26108690
23.

Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered.

Zeijlemaker W, Kelder A, Wouters R, Valk PJM, Witte BI, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Br J Haematol. 2015 Oct;171(2):227-238. doi: 10.1111/bjh.13572. Epub 2015 Jun 24.

PMID:
26104974
24.

Gene expression profiles associated with pediatric relapsed AML.

Bachas C, Schuurhuis GJ, Zwaan CM, van den Heuvel-Eibrink MM, den Boer ML, de Bont ES, Kwidama ZJ, Reinhardt D, Creutzig U, de Haas V, Kaspers GJ, Cloos J.

PLoS One. 2015 Apr 7;10(4):e0121730. doi: 10.1371/journal.pone.0121730. eCollection 2015.

25.

MRD in AML: it is time to change the definition of remission.

Ossenkoppele GJ, Schuurhuis GJ.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):265-71. doi: 10.1016/j.beha.2014.10.008. Epub 2014 Oct 15. Review.

PMID:
25455276
26.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

PLoS One. 2014 Sep 22;9(9):e107587. doi: 10.1371/journal.pone.0107587. eCollection 2014.

27.

Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.

Wouters R, Cucchi D, Kaspers GJ, Schuurhuis GJ, Cloos J.

Expert Rev Hematol. 2014 Dec;7(6):791-805. doi: 10.1586/17474086.2014.959921. Epub 2014 Sep 22. Review.

PMID:
25242511
28.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

29.

IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival.

Verhagen HJ, de Leeuw DC, Roemer MG, Denkers F, Pouwels W, Rutten A, Celie PH, Ossenkoppele GJ, Schuurhuis GJ, Smit L.

Cell Death Dis. 2014 Jun 26;5:e1300. doi: 10.1038/cddis.2014.268.

30.

Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse.

Bachas C, Schuurhuis GJ, Reinhardt D, Creutzig U, Kwidama ZJ, Zwaan CM, van den Heuvel-Eibrink MM, De Bont ES, Elitzur S, Rizzari C, de Haas V, Zimmermann M, Cloos J, Kaspers GJ.

Br J Haematol. 2014 Sep;166(6):902-10. doi: 10.1111/bjh.12989. Epub 2014 Jun 25.

PMID:
24962064
31.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25.

PMID:
24731748
32.

Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.

de Leeuw DC, Denkers F, Olthof MC, Rutten AP, Pouwels W, Schuurhuis GJ, Ossenkoppele GJ, Smit L.

Cancer Res. 2014 Apr 1;74(7):2094-105. doi: 10.1158/0008-5472.CAN-13-1733. Epub 2014 Jan 29.

33.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.

PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013.

34.

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.

Zeijlemaker W, Gratama JW, Schuurhuis GJ.

Cytometry B Clin Cytom. 2014 Jan;86(1):3-14. doi: 10.1002/cyto.b.21134. Epub 2013 Oct 21. Review.

35.

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.

Zeijlemaker W, Gratama JW, Schuurhuis GJ.

Cytometry B Clin Cytom. 2013 Oct 5. doi: 10.1002/cytob.21134. [Epub ahead of print]

36.

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E.

Cancer Res. 2013 Nov 15;73(22):6745-56. doi: 10.1158/0008-5472.CAN-13-0837. Epub 2013 Oct 1.

37.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
38.

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting.

Feller N, van der Velden VH, Brooimans RA, Boeckx N, Preijers F, Kelder A, de Greef I, Westra G, Te Marvelde JG, Aerts P, Wind H, Leenders M, Gratama JW, Schuurhuis GJ.

Blood Cancer J. 2013 Aug 2;3:e129. doi: 10.1038/bcj.2013.27.

39.

Highly effective mobilization of CD34 positive cells as a poor prognostic factor in acute myeloid leukemia. Possible causes and consequences.

Schuurhuis GJ, Zweegman S, Ossenkoppele GJ.

Leuk Res. 2013 Jul;37(7):727-8. doi: 10.1016/j.leukres.2013.03.020. Epub 2013 Apr 28. No abstract available.

PMID:
23628551
40.

How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?

Schuurhuis GJ, Cloos J, Ossenkoppele GJ.

Transl Pediatr. 2013 Apr;2(2):80-3. doi: 10.3978/j.issn.2224-4336.2013.04.09. No abstract available.

41.

CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties.

Martens-de Kemp SR, Brink A, Stigter-van Walsum M, Damen JM, Rustenburg F, Wu T, van Wieringen WN, Schuurhuis GJ, Braakhuis BJ, Slijper M, Brakenhoff RH.

Stem Cell Res. 2013 May;10(3):477-88. doi: 10.1016/j.scr.2013.02.004. Epub 2013 Feb 18.

42.

MRD in AML: time for redefinition of CR?

Ossenkoppele G, Schuurhuis GJ.

Blood. 2013 Mar 21;121(12):2166-8. doi: 10.1182/blood-2013-01-480590. No abstract available.

43.

Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.

PMID:
23051844
44.

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R.

J Clin Oncol. 2013 Jan 1;31(1):95-103. doi: 10.1200/JCO.2011.41.5505. Epub 2012 Sep 24.

PMID:
23008312
45.

Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.

Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, Giovannetti E.

Curr Pharm Des. 2013;19(5):940-50.

PMID:
22973962
46.

The adverse prognosis for acute myeloid leukemia patients with superior autologous stem cell mobilization.

Schuurhuis GJ, Zweegman S, Ossenkoppele GJ.

Leuk Res. 2012 Nov;36(11):1323-4. doi: 10.1016/j.leukres.2012.07.010. Epub 2012 Aug 29. No abstract available.

PMID:
22938942
47.

The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.

van Dijk A, Naaijkens BA, Jurgens WJ, Oerlemans R, Scheffer GL, Kassies J, Aznou J, Brouwer M, van Rossum AC, Schuurhuis GJ, van Milligen FJ, Niessen HW.

Cell Biol Toxicol. 2012 Oct;28(5):303-15. doi: 10.1007/s10565-012-9225-y. Epub 2012 Jul 17.

PMID:
22801743
48.

Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.

Terwijn M, Kelder A, Snel AN, Rutten AP, Scholten WJ, Oussoren YJ, Van De Loosdrecht AA, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

Int J Lab Hematol. 2012 Aug;34(4):432-41. doi: 10.1111/j.1751-553X.2012.01416.x. Epub 2012 Apr 4.

PMID:
22471741
49.

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse.

Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, Wouters F, Snel AN, Kaspers GJ, Cloos J.

Leukemia. 2012 Jun;26(6):1313-20. doi: 10.1038/leu.2011.383. Epub 2012 Jan 13.

PMID:
22289983
50.

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.

Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ.

Leukemia. 2012 May;26(5):977-84. doi: 10.1038/leu.2011.347. Epub 2011 Dec 9.

PMID:
22157734

Supplemental Content

Loading ...
Support Center